Antisoma has said it will halt trials of its non-small cell lung cancer drug candidate ASA404 following poor interim data analysis from Phase III trials.
The interim analysis indicated that the continuation of the trial would be futile as the drug candidate showed little or no prospect of survival benefit.
Go deeper with GlobalData
The study coded Attract-1 has not revealed new or unexpected serious adverse effects.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
